Clinical trials

8

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study

This project examines the use of repetitive transcranial magnetic stimulation (rTMS) as a therapeutic approach to improve motor function in children with cerebral palsy (CP). By applying 6-Hz primed low and high-frequency rTMS and measuring brain responses through TMS-EEG, the study aims to enhance neural plasticity and motor recovery. The goal is to promote faster rehabilitation and reduce long-term healthcare needs.

Participants needed: 60
Trial details
Age: 6-20Biological sex: AllType: InterventionalSponsor: Cook Children's Health Care SystemUpdated: May 14, 2026Locations: 1
Eligibility criteria

Aged 6 - 20 years, [+7]

Syndromic or genetic brain-related associations, [+16]

Status: Not yet recruiting

Effect of Ipratropium Bromide on EILO

The investigators propose a study that compares breathlessness and airway obstruction during intense exercise in 34 children and adolescents with Exercise-Induced Laryngeal Obstruction after breathing in ipratropium bromide or placebo. It is hypothesized that breathlessness and airway obstruction will be lower following breathing in ipratropium bromide compared with placebo.

Participants needed: 50
Trial details
Phase: Phase 2Age: 8-17Biological sex: AllType: InterventionalSponsor: Cook Children's Health Care SystemUpdated: May 5, 2026Locations: 1
Eligibility criteria

Patients must be diagnosed with EILO confirmed by Continuous Laryngoscopy During... [+3]

Patients that do not have EILO. [+7]

Status: Recruiting

Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recently diagnosed Langerhans Cell Histiocytosis (LCH) among pediatric patients.

Participants needed: 75
Trial details
Phase: Phase 2Age: 1-30Biological sex: AllType: InterventionalSponsor: Cook Children's Health Care SystemUpdated: Apr 7, 2026Locations: 1
Eligibility criteria

Patients with newly diagnosed Langerhans cell histiocytosis (LCH) OR [+18]

CNS-risk/special site includes: Sphenoid, Mastoid, Orbital, zygomatic, ethmoid,... [+11]

Status: Not yet recruiting

Ex-vivo Confocal Imaging and Proteomic Profiling to Determine Treatment Response in Children With IBD

This study aims to test the overall hypothesis that the membrane tissue binding capacity of cytokines in the biopsied tissue of patients with Inflammatory Bowel Disease (IBD) is predictive of/strongly correlated to clinical response/outcomes observed. The key questions under investigation are: Aim 1: To assess the fluorescent signal intensity at baseline (control antibody with control biopsy and control antibody with IBD biopsy). Aim 2: To characterize the cellular landscape by surveying surface markers using bar-coded antibodies and performing gene expression profiling on every cell within inflamed tissue of patients with IBD. Aim 3: Develop algorithm using artificial intelligence to predict responders versus non-responders and to further subclassify IBD patients using phenotype data.

Participants needed: 40
Trial details
Age: 2-21Biological sex: AllType: InterventionalSponsor: Cook Children's Health Care SystemUpdated: Aug 14, 2025Locations: 2
Eligibility criteria

Those with previous allergy to fluorescein [+1]

Status: Not yet recruiting

Endomicroscopic Evaluation of Food-induced Gastrointestinal Mucosal Alteration

The overarching goal of this study is to establish a first ever registry in the U.S. to collect outcomes data to evaluate changes in the gastrointestinal (GI) mucosa following direct food application utilizing Confocal Laser Endomicroscopy (CLE). This will be assessed in pediatric and adult patients who present to the outpatient clinic with persistent irritable bowel syndrome-like symptoms while testing negative for celiac disease and have either negative or very low/low levels of Immunoglobulin E (IgE) serological tests.

Participants needed: 200
Trial details
Age: 2-99Biological sex: AllType: InterventionalSponsor: Cook Children's Health Care SystemUpdated: Feb 24, 2025
Eligibility criteria

Adults and children presenting with a prolonged history of IBS-like symptoms (as... [+2]

If patient had a previous Esophagogastroduodenoscopy (EGD) and Colonoscopy with... [+4]

Status: Recruiting

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

Low blood sugars are known to cause brain damage in newborn babies. One of the most common causes of low blood sugars persisting beyond the new born period is a condition called congenital hyperinsulinism (HI). This is a disease whereby the pancreas secretes too much insulin and causes low blood sugars. Twenty to forty percent of these babies will have brain damage. There are two forms of this disease. In one form only a small part of the pancreas makes too much insulin (focal HI) and in the other, the whole pancreas make too much insulin (diffuse HI). Another very similar disease is insulinoma which occurs after birth, but also causes hyperinsulinism. If a surgeon could know which part of the pancreas has the focal lesion he could remove it and cure the patient. The purpose of this study is to investigate whether a new investigational drug called Fluorodopa F 18, when used with a PET scan, can find the focal lesion and guide the surgeon to remove it, thus curing the patient and preventing further brain damage.

Participants needed: 250
Trial details
Phase: Phase 1Age: Up to 18Biological sex: AllType: InterventionalSponsor: Cook Children's Health Care SystemUpdated: Jul 16, 2024Locations: 1
Eligibility criteria

Patients with HI attending the Cook Children's Congenital Hyperinsulinism Center... [+7]

Patients who do not have a diagnosis of HI [+4]

Status: Recruiting

Massage Therapy After Thoracic or Lumbar Surgery

The purpose of this research is to look at the effect of massage therapy on the pain, anxiety, and quality of life that pediatric patients have after undergoing spinal fusion surgery. This is a single-site, prospective, randomized, interventional study design that will involve post-thoracic and post-lumbar spinal fusion surgeries of pediatric patients from 7 to 19 years of age that present to Cook Children's Medical Center in Fort Worth, Texas. These patients will be identified prior to their scheduled spinal fusion surgery and recruited to enroll in the study. The planned spinal fusion surgeries are not considered part of this research project, but rather considered standard of care and would occur whether the patient is enrolled in this project or not. Enrolled participants will be followed during their inpatient stay and through their subsequent follow-up visits at weeks 2, 6, and 12. Participants will be randomly assigned to either a massage therapy group or a group that receives the standard (normal) care for recovery after surgery. The final study involvement will occur at week 16 (post-hospital discharge) where a study team member will administer a quality of life (PedsQL) questionnaire via phone or mail with the subject. Data will be collected after study related procedures are completed.

Participants needed: 100
Trial details
Age: 7-19Biological sex: AllType: InterventionalSponsor: Cook Children's Health Care SystemUpdated: May 23, 2024Locations: 1
Eligibility criteria

Patients scheduled to undergo their first thoracic or lumbar spinal fusion surge... [+3]

Prospective patients scheduled to undergo any spinal fusion other than a thoraci... [+13]

Status: Recruiting

GABA Biomarkers in Dravet Syndrome

This study will non-invasively obtain levels of GABA in the brain of children with SCN1A+DS and neurodeveloping children through evoked and induced cortical responses, correlate them with the BOLD responses, and with the levels of GABA in their blood.

Participants needed: 36
Trial details
Age: Up to 18Biological sex: AllType: ObservationalSponsor: Cook Children's Health Care SystemUpdated: Dec 14, 2022Locations: 1
Eligibility criteria

Authorized representative (parent/caregiver) must be willing and able to give in... [+6]

Participant has a copy number variant of SCN1A, including SCN1A microdeletion, a... [+9]